RXR-LXR heterodimer modulators for the potential treatment of dyslipidemia.
A number of RXR agonists were synthesized and screened in functional assays. The synthesis and the structure-activity relationship (SAR) within the series of compounds will be presented. Some in vivo data in rodent models for dyslipidemia and diabetes will also be presented.
Lagu
Bharat
B
Johnson and Johnson Pharmaceutical Research and Development, Cranbury, NJ 08869, USA. blagu@prdus.jnj.com
Pio
Barbara
B
Lebedev
Rimma
R
Yang
Maria
M
Pelton
Patricia D
PD
D000818:Animals; D004268:DNA-Binding Proteins / Q000819:agonists* / Q000378:metabolism; D003920:Diabetes Mellitus / Q000188:drug therapy*; D019281:Dimerization; D004195:Disease Models, Animal; D050171:Dyslipidemias / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D051381:Rats; D017207:Rats, Sprague-Dawley; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists* / Q000378:metabolism; D047488:Retinoid X Receptors / Q000819:agonists* / Q000378:metabolism; D013329:Structure-Activity Relationship
D004268:DNA-Binding Proteins; D007004:Hypoglycemic Agents; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D018160:Receptors, Cytoplasmic and Nuclear; D047488:Retinoid X Receptors